Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vimal H Prajapati

Showing results (41-50 of 105) with videos related to

Pageof 11
Sort By:
JAAD International|November 24, 2021
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort studyYuliya Lytvyn, Asfandyar Mufti, Hiba Zaaroura, et al.
JAAD International|May 22, 2024
Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based reviewSiddhartha Sood, Ahmed Bagit, Martin Heung, et al.
JAAD International|July 6, 2023
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor classAhmed Bagit, Khalad Maliyar, Jorge R Georgakopoulos, et al.
Journal of the American Academy of Dermatology|January 26, 2025
Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective studySiddhartha Sood, Marni Wiseman, Ahmed Bagit, et al.
Journal of the American Academy of Dermatology|February 5, 2025
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled studyLindsay S Ackerman, Bethanee J Schlosser, Tianyu Zhan, et al.
Journal of the American Academy of Dermatology|October 25, 2021
Management of pediatric generalized pustular psoriasis using biologics: An evidence-based reviewMuskaan Sachdeva, Brian D Rankin, Asfandyar Mufti, et al.
Journal of the American Academy of Dermatology|September 18, 2024
Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based reviewSiddhartha Sood, Jaymie Varenbut, Ahmed Bagit, et al.
Journal of Cutaneous Medicine and Surgery|February 15, 2025
Management of Chronic Prurigo and Prurigo Nodularis with Systemic Janus Kinase Inhibitors: An Evidence-Based ReviewSiddhartha Sood, Ryan S Q Geng, Martin Heung, et al.
Dermatology and Therapy|December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE RegistryMelinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of the American Academy of Dermatology|June 17, 2022
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trialsPedro Mendes-Bastos, Barry Ladizinski, Emma Guttman-Yassky, et al.
Pageof 11

Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
JAAD International|November 24, 2021
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort studyYuliya Lytvyn, Asfandyar Mufti, Hiba Zaaroura, et al.
JAAD International|May 22, 2024
Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based reviewSiddhartha Sood, Ahmed Bagit, Martin Heung, et al.
JAAD International|July 6, 2023
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor classAhmed Bagit, Khalad Maliyar, Jorge R Georgakopoulos, et al.
Journal of the American Academy of Dermatology|January 26, 2025
Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective studySiddhartha Sood, Marni Wiseman, Ahmed Bagit, et al.
Journal of the American Academy of Dermatology|February 5, 2025
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled studyLindsay S Ackerman, Bethanee J Schlosser, Tianyu Zhan, et al.
Journal of the American Academy of Dermatology|October 25, 2021
Management of pediatric generalized pustular psoriasis using biologics: An evidence-based reviewMuskaan Sachdeva, Brian D Rankin, Asfandyar Mufti, et al.
Journal of the American Academy of Dermatology|September 18, 2024
Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based reviewSiddhartha Sood, Jaymie Varenbut, Ahmed Bagit, et al.
Journal of Cutaneous Medicine and Surgery|February 15, 2025
Management of Chronic Prurigo and Prurigo Nodularis with Systemic Janus Kinase Inhibitors: An Evidence-Based ReviewSiddhartha Sood, Ryan S Q Geng, Martin Heung, et al.
Dermatology and Therapy|December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE RegistryMelinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of the American Academy of Dermatology|June 17, 2022
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trialsPedro Mendes-Bastos, Barry Ladizinski, Emma Guttman-Yassky, et al.
Pageof 11